Literature DB >> 21506049

Epidemiology of infections acquired in intensive care units.

Joseph S Doyle1, Kirsty L Buising, Karin A Thursky, Leon J Worth, Michael J Richards.   

Abstract

Infections acquired in the intensive care unit (ICU) are associated with significant morbidity and mortality. Using surveillance data collected in the United States and internationally, we describe contemporary rates, sites, and pathogens responsible for common ICU-acquired infections. Emerging pathogens are outlined, including a systematic review of published ICU infection outbreaks from 2005 to 2010. Compared with a similar review of outbreaks conducted in 2003, multiresistant gram-negative bacteria (eg, ACINETOBACTER and PSEUDOMONAS species) were more commonly reported, whereas resistant STAPHYLOCOCCUS AUREUS was reported less frequently. Advances in ICU infection prevention, including central line bundles, chlorhexidine body wash, and hand hygiene interventions occurred during this period. We also describe how changes in the pattern of antimicrobial use can affect the prevalence of multiresistant pathogens. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506049     DOI: 10.1055/s-0031-1275525

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  34 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

Review 2.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

3.  Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection.

Authors:  Brittany L Mortensen; Eric P Skaar
Journal:  Cell Microbiol       Date:  2012-06-14       Impact factor: 3.715

Review 4.  Antimicrobial hydrogels for the treatment of infection.

Authors:  Ana Salomé Veiga; Joel P Schneider
Journal:  Biopolymers       Date:  2013-11       Impact factor: 2.505

5.  Antimicrobial Resistance Surveillance among Intensive Care Units of a Tertiary Care Hospital in Southern India.

Authors:  Kailash Moolchandani; Apurba Sankar Sastry; R Deepashree; Sujatha Sistla; B N Harish; Jharna Mandal
Journal:  J Clin Diagn Res       Date:  2017-02-01

6.  Fluorescence High-Throughput Screening for Inhibitors of TonB Action.

Authors:  Brittany L Nairn; Olivia S Eliasson; Dallas R Hyder; Noah J Long; Aritri Majumdar; Somnath Chakravorty; Peter McDonald; Anuradha Roy; Salete M Newton; Phillip E Klebba
Journal:  J Bacteriol       Date:  2017-04-25       Impact factor: 3.490

7.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

8.  Arginine-rich self-assembling peptides as potent antibacterial gels.

Authors:  Ana Salomé Veiga; Chomdao Sinthuvanich; Diana Gaspar; Henri G Franquelim; Miguel A R B Castanho; Joel P Schneider
Journal:  Biomaterials       Date:  2012-09-17       Impact factor: 12.479

9.  Acinetobacter baumannii response to host-mediated zinc limitation requires the transcriptional regulator Zur.

Authors:  Brittany L Mortensen; Subodh Rathi; Walter J Chazin; Eric P Skaar
Journal:  J Bacteriol       Date:  2014-05-09       Impact factor: 3.490

10.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.